Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.

Henrik GregersenValdas PeceliunasKari RemesSchjesvold FredrikNiels AbildgaardHareth NahiNiels Frost AndersenAnnette Juul VangstedTobias Wirenfeldt KlausenCarsten HellebergKristina CarlsonUlf Christian FrølundPer AxelssonOlga StrombergCecilie Hveding BlimarkJacob CrafoordGalina TsykunovaHenrik Rode EshojAnders WaageMarkus HanssonNina Gulbrandsen

Published in: European journal of haematology (2021)

In summary, maintenance therapy with carfilzomib and dexamethasone after salvage ASCT prolonged TTP with 8 months. The maintenance treatment was in general well-tolerated with manageable toxicity.

Keyphrases

multiple myeloma
low dose
high dose
clinical trial
open label
oxidative stress
double blind
mesenchymal stem cells
placebo controlled
cell therapy